T1	PROC 83 94	tratamiento
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	DISO 131 161	insuficiencia cardíaca crónica
#2	AnnotatorNotes T2	C0264716; Chronic heart failure; Disease or Syndrome
T3	CHEM 107 113	LCZ696
#3	AnnotatorNotes T3	C2933615; LCZ 696; Organic Chemical
T4	DISO 164 200	reducción de la fracción de eyección
T5	PROC 223 251	Ensayo clínico multicéntrico
T6	PROC 257 296	evaluar la seguridad y la tolerabilidad
T7	DISO 314 344	insuficiencia cardíaca crónica
#4	AnnotatorNotes T7	C0264716; Chronic heart failure; Disease or Syndrome
T8	DISO 347 383	reducción de la fracción de eyección
T9	CHEM 435 441	LCZ696
#5	AnnotatorNotes T9	C2933615; LCZ 696; Organic Chemical
T10	PROC 411 422	tratamiento
#6	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	DISO 465 487	Insuficiencia cardiaca
#7	AnnotatorNotes T11	C0018801; Heart failure; Disease or Syndrome
T12	DISO 514 536	Insuficiencia cardíaca
#8	AnnotatorNotes T12	C0018801; Heart failure; Disease or Syndrome
T13	DISO 541 570	fracción de eyección reducida
T14	PROC 707 717	evaluación
#9	AnnotatorNotes T14	C1261322; Evaluation procedure; Health Care Activity
T15	PROC 620 656	consentimiento informado por escrito
#10	AnnotatorNotes T15	C0811741; Obtain informed written consent; Health Care Activity
T16	PROC 825 840	estudio abierto
#11	AnnotatorNotes T16	C1709323; Open Label Study; Research Activity
T17	CHEM 912 941	medicamentos en investigación
#12	AnnotatorNotes T17	C0013230; Investigational New Drugs; Pharmacologic Substance
T18	DISO 1079 1096	hipersensibilidad
#13	AnnotatorNotes T18	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T19	DISO 1099 1106	alergia
#14	AnnotatorNotes T19	C1527304; Allergic Reaction; Pathologic Function
T20	CHEM 1261 1267	LCZ696
#15	AnnotatorNotes T20	C2933615; LCZ 696; Organic Chemical
T21	CHEM 1136 1144	fármacos
#16	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T22	CHEM 1175 1179	IECA
#17	AnnotatorNotes T22	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T23	CHEM 1187 1208	inhibidores de la EPN
T24	DISO 1298 1308	angioedema
#18	AnnotatorNotes T24	C0002994; Angioedema; Pathologic Function
T25	PROC 1326 1337	tratamiento
#19	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	CHEM 1353 1357	IECA
#20	AnnotatorNotes T26	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T27	PROC 1587 1598	FG estimada
T28	DISO 1399 1411	exacerbación
#21	AnnotatorNotes T28	C2825055; Recurrence (disease attribute); Pathologic Function (?)
T29	DISO 1446 1463	signos y síntomas
#22	AnnotatorNotes T29	C0037088; Signs and Symptoms; Sign or Symptom
T30	PROC 1484 1507	tratamiento intravenoso
#23	AnnotatorNotes T30	C0455142; Intravenous therapy; Therapeutic or Preventive Procedure | C1273557; Intravenous administration of treatment; Therapeutic or Preventive Procedure
T31	DISO 1513 1536	Hipotensión sintomática
#24	AnnotatorNotes T31	C0863113; Hypotension symptomatic; Pathologic Function
T32	CHEM 1360 1363	ARA
#25	AnnotatorNotes T32	C0815017; Angiotensin Receptor Antagonists; Pharmacologic Substance
T33	DISO 1710 1739	estenosis de la arteria renal
#26	AnnotatorNotes T33	C0035067; Renal Artery Stenosis; Disease or Syndrome
T34	CHEM 1753 1760	Potasio
#27	AnnotatorNotes T34	C0032821; potassium; Biologically Active Substance · Element, Ion, or Isotope · Pharmacologic Substance
T35	ANAT 1761 1767	sérico
#28	AnnotatorNotes T35	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T36	DISO 1812 1833	Signos de hepatopatía
T37	PROC 1888 1902	Valores de AST
T38	DISO 1951 1973	encefalopatía hepática
#29	AnnotatorNotes T38	C0019151; Hepatic Encephalopathy; Disease or Syndrome
T39	DISO 1991 2009	varices esofágicas
#30	AnnotatorNotes T39	C0014867; Esophageal Varices; Disease or Syndrome
T40	PROC 2028 2048	derivación portocava
#31	AnnotatorNotes T40	C0032716; Surgical Portacaval Shunt (procedure); Therapeutic or Preventive Procedure
T41	CHEM 2478 2484	LCZ696
#32	AnnotatorNotes T41	C2933615; LCZ 696; Organic Chemical
T42	PROC 2233 2248	análisis de HCG
T43	DISO 2381 2390	trastorno
#33	AnnotatorNotes T43	C0012634; Disease; Disease or Syndrome
T44	ANAT 145 153	cardíaca
#34	AnnotatorNotes T44	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T45	ANAT 328 336	cardíaca
#35	AnnotatorNotes T45	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T46	ANAT 479 487	cardiaca
#36	AnnotatorNotes T46	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T47	ANAT 528 536	cardíaca
#37	AnnotatorNotes T47	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T48	CHEM 1115 1122	fármaco
#38	AnnotatorNotes T48	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T49	CHEM 1181 1184	ARA
#39	AnnotatorNotes T49	C0815017; Angiotensin Receptor Antagonists; Pharmacologic Substance
T50	DISO 1368 1390	IC aguda descompensada
#40	AnnotatorNotes T50	C1609524; Acute Decompensated Heart Failure; Disease or Syndrome
T51	DISO 1419 1429	IC crónica
T52	PROC 1541 1544	PAS
#41	AnnotatorNotes T52	C1306620; Systolic blood pressure measurement; Diagnostic Procedure
T53	ANAT 1726 1739	arteria renal
#42	AnnotatorNotes T53	C0035065; Structure of renal artery; Body Part, Organ, or Organ Component | C1278951; Entire renal artery; Body Part, Organ, or Organ Component
T54	PROC 1753 1767	Potasio sérico
#43	AnnotatorNotes T54	C0302353; Serum potassium measurement; Laboratory Procedure
T55	PROC 1641 1653	fórmula MDRD
T56	PROC 1905 1908	ALT
#44	AnnotatorNotes T56	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T57	ANAT 1965 1973	hepática
#45	AnnotatorNotes T57	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T58	ANAT 1999 2009	esofágicas
#46	AnnotatorNotes T58	C0014876; Esophagus; Body Part, Organ, or Organ Component | C1278919; Entire esophagus; Body Part, Organ, or Organ Component
T59	CHEM 2245 2248	HCG
#47	AnnotatorNotes T59	C1141639; human chorionic gonadotropin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T60	Date 13 17	2014
T61	LIVB 117 126	pacientes
#48	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	Duration 154 161	crónica
#49	AnnotatorNotes T62	C0205191; chronic; Temporal Concept
T63	LIVB 300 309	pacientes
#50	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Duration 337 344	crónica
#51	AnnotatorNotes T64	C0205191; chronic; Temporal Concept
T66	LIVB 722 731	Pacientes
#52	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T68	LIVB 856 868	investigador
#53	AnnotatorNotes T68	C0035173; Research Personnel; Professional or Occupational Group
T69	Duration 990 997	30 días
T70	Duration 1000 1011	5 semividas
T72	Date 1391 1397	actual
T73	Duration 1422 1429	crónica
#54	AnnotatorNotes T73	C0205191; chronic; Temporal Concept
T74	Spec_cue 1468 1474	puedan
T75	Route 1496 1507	intravenoso
#55	AnnotatorNotes T75	C1522726; Intravenous Route of Drug Administration; Functional Concept
T78	LIVB 2054 2073	Mujeres embarazadas
#56	AnnotatorNotes T78	C0033011; Pregnant Women; Population Group
T79	PHYS 2102 2110	embarazo
#57	AnnotatorNotes T79	C0032961; Pregnancy; Organism Function
T80	LIVB 2132 2137	mujer
#58	AnnotatorNotes T80	C0043210; Woman; Population Group
T81	PHYS 2147 2157	concepción
#59	AnnotatorNotes T81	C0009637; Conception; Organism Function | C0015914; Fertilization; Organism Function
T82	PHYS 2179 2188	gestación
#60	AnnotatorNotes T82	C0032961; Pregnancy; Organism Function
T83	PHYS 2079 2088	lactación
#61	AnnotatorNotes T83	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T84	LIVB 2267 2289	Mujeres en edad fértil
#62	AnnotatorNotes T84	C4324275; Woman of childbearing potential; Population Group
T85	Age 2278 2289	edad fértil
T86	PHYS 2062 2073	embarazadas
#63	AnnotatorNotes T86	C0032961; Pregnancy; Organism Function
T87	LIVB 2411 2423	investigador
#64	AnnotatorNotes T87	C0035173; Research Personnel; Professional or Occupational Group
T90	LIVB 2446 2454	paciente
#65	AnnotatorNotes T90	C0030705; Patients; Patient or Disabled Group
T91	PHYS 363 383	fracción de eyección
#66	AnnotatorNotes T91	C0232174; Cardiac ejection fraction; Organ or Tissue Function
T93	PHYS 541 561	fracción de eyección
#67	AnnotatorNotes T93	C0232174; Cardiac ejection fraction; Organ or Tissue Function
T94	PHYS 2321 2366	capacidad fisiológica de quedarse embarazadas
#68	AnnotatorNotes T94	C3831118; Childbearing Potential; Clinical Attribute
T67	PHYS 180 200	fracción de eyección
#69	AnnotatorNotes T67	C0232174; Cardiac ejection fraction; Organ or Tissue Function
T71	PHYS 1587 1589	FG
#70	AnnotatorNotes T71	C0232809; Glomerular filtration; Organ or Tissue Function
T76	PROC 1023 1036	reclutamiento
#71	AnnotatorNotes T76	C0242800; Patient Recruitment; Research Activity
T77	PROC 1673 1679	visita
#72	AnnotatorNotes T77	C1512346; Patient Visit; Health Care Activity
T88	PROC 1562 1568	visita
#73	AnnotatorNotes T88	C1512346; Patient Visit; Health Care Activity
T89	PROC 1787 1793	visita
#74	AnnotatorNotes T89	C1512346; Patient Visit; Health Care Activity
T92	PROC 1925 1931	visita
#75	AnnotatorNotes T92	C1512346; Patient Visit; Health Care Activity
T95	Quantifier_or_Qualifier 1680 1681	1
T96	Quantifier_or_Qualifier 1569 1570	1
T97	Quantifier_or_Qualifier 1932 1933	1
T98	Quantifier_or_Qualifier 1794 1795	1
A2	Assertion T30 Speculated
A3	Status T19 History_of
A4	Status T18 History_of
A5	Assertion T20 Contraindicated
A6	Status T24 History_of
A7	Status T20 History_of
A8	Status T38 History_of
A9	Status T39 History_of
A10	Status T40 History_of
#80	AnnotatorNotes T5	C1096776; Multicenter Study; Research Activity + C0008976; Clinical Trials; Research Activity
#81	AnnotatorNotes T6	C1705187; Safety Study; Research Activity + C3274448; Tolerability Study; Research Activity 
#82	AnnotatorNotes T4	C4022792; Reduced ejection fraction; Finding  
#83	AnnotatorNotes T8	C4022792; Reduced ejection fraction; Finding  
#84	AnnotatorNotes T13	C4022792; Reduced ejection fraction; Finding  
#85	AnnotatorNotes T72	C0521116; Current (present time); Temporal Concept 
#86	AnnotatorNotes T51	C0264716; Chronic heart failure; Disease or Syndrome
#87	AnnotatorNotes T27	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
#88	AnnotatorNotes T55	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
#89	AnnotatorNotes T37	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
#90	AnnotatorNotes T42	C0428402; Human chorionic gonadotropin measurement; Laboratory Procedure
T99	CONC 1218 1236	contraindicaciones
A11	Assertion T99 Speculated
#76	AnnotatorNotes T99	C0522473; Contraindication; Qualitative Concept
T100	Spec_cue 1237 1246	presuntas
T101	Observation 2455 2461	tolere
T102	Quantifier_or_Qualifier 2462 2477	de forma segura
A12	Assertion T102 Negated
A13	Assertion T101 Negated
R1	Experiences Arg1:T90 Arg2:T101	
R2	Has_Quantifier_or_Qualifier Arg1:T101 Arg2:T102	
T103	Neg_cue 2431 2438	impedir
R3	Negation Arg1:T103 Arg2:T101	
R4	Negation Arg1:T103 Arg2:T102	
R5	Speculation Arg1:T100 Arg2:T99	
R6	Speculation Arg1:T74 Arg2:T30	
A1	Assertion T75 Speculated
R7	Speculation Arg1:T74 Arg2:T75	
T65	Observation 2487 2521	cumplir los requisitos del estudio
A14	Assertion T65 Negated
R8	Negation Arg1:T103 Arg2:T65	
#77	AnnotatorNotes T65	C2364172; Adherence To Medication Regime; Finding
R9	Used_for Arg1:T3 Arg2:T1	
R10	Experiences Arg1:T61 Arg2:T1	
R11	Experiences Arg1:T61 Arg2:T2	
R12	Location_of Arg1:T44 Arg2:T2	
R13	Has_Duration_or_Interval Arg1:T2 Arg2:T62	
R14	Experiences Arg1:T61 Arg2:T4	
R15	Experiences Arg1:T61 Arg2:T67	
R17	Overlap Arg1:T2 Arg2:T4	
R18	Experiences Arg1:T63 Arg2:T7	
R19	Location_of Arg1:T45 Arg2:T7	
R20	Has_Duration_or_Interval Arg1:T7 Arg2:T64	
R21	Experiences Arg1:T63 Arg2:T8	
R22	Overlap Arg1:T7 Arg2:T8	
R23	Experiences Arg1:T63 Arg2:T91	
R25	Experiences Arg1:T63 Arg2:T10	
R26	Used_for Arg1:T9 Arg2:T10	
R27	Location_of Arg1:T46 Arg2:T11	
R28	Location_of Arg1:T47 Arg2:T12	
R29	Overlap Arg1:T12 Arg2:T13	
R31	Location_of Arg1:T44 Arg2:T4	
R32	Location_of Arg1:T45 Arg2:T8	
R33	Location_of Arg1:T47 Arg2:T13	
R34	Before Arg1:T15 Arg2:T14	
T104	Observation 742 763	finalizado el estudio
#78	AnnotatorNotes T104	C2732579; Completion of clinical trial; Finding
R35	Before Arg1:T104 Arg2:T16	
T105	CONC 962 971	inclusión
#79	AnnotatorNotes T105	C1512693; Inclusion; Qualitative Concept
R36	Overlap Arg1:T17 Arg2:T105	
R37	Overlap Arg1:T17 Arg2:T69	
R38	Before Arg1:T17 Arg2:T76	
R39	Has_Duration_or_Interval Arg1:T17 Arg2:T70	
R40	Causes Arg1:T48 Arg2:T18	
R41	Causes Arg1:T21 Arg2:T18	
R42	Causes Arg1:T48 Arg2:T19	
R43	Causes Arg1:T21 Arg2:T19	
T106	Quantifier_or_Qualifier 1145 1173	de grupos químicos similares
R44	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T106	
R45	Causes Arg1:T22 Arg2:T18	
R46	Causes Arg1:T22 Arg2:T19	
R47	Causes Arg1:T49 Arg2:T18	
R48	Causes Arg1:T49 Arg2:T19	
R49	Causes Arg1:T23 Arg2:T18	
R50	Causes Arg1:T23 Arg2:T19	
#91	AnnotatorNotes T23	['neutral endopeptidase (NEP) inhibitor']
R51	Overlap Arg1:T26 Arg2:T32	
R52	Used_for Arg1:T26 Arg2:T25	
R53	Used_for Arg1:T32 Arg2:T25	
T107	Quantifier_or_Qualifier 1338 1348	simultáneo
#92	AnnotatorNotes T107	C0521115; Simultaneous; Temporal Concept
R54	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T107	
R55	Overlap Arg1:T50 Arg2:T72	
R56	Before Arg1:T51 Arg2:T28	
R57	Has_Duration_or_Interval Arg1:T51 Arg2:T73	
R58	Causes Arg1:T28 Arg2:T29	
R59	Overlap Arg1:T28 Arg2:T72	
R60	Overlap Arg1:T51 Arg2:T72	
R61	Overlap Arg1:T29 Arg2:T72	
R62	Has_Route_or_Mode Arg1:T30 Arg2:T75	
T108	Result_or_Value 1545 1555	< 100 mmHg
R63	Has_Result_or_Value Arg1:T52 Arg2:T108	
R64	Has_Quantifier_or_Qualifier Arg1:T88 Arg2:T96	
R66	Overlap Arg1:T31 Arg2:T88	
R67	Overlap Arg1:T52 Arg2:T88	
T109	PROC 1572 1581	selección
#93	AnnotatorNotes T109	C0242802; Patient Selection; Research Activity
R68	Overlap Arg1:T31 Arg2:T109	
R69	Overlap Arg1:T52 Arg2:T109	
R70	Has_Quantifier_or_Qualifier Arg1:T77 Arg2:T95	
T110	PROC 1683 1692	selección
#94	AnnotatorNotes T110	C0242802; Patient Selection; Research Activity
T111	PROC 1797 1806	selección
#95	AnnotatorNotes T111	C0242802; Patient Selection; Research Activity
R71	Overlap Arg1:T88 Arg2:T109	
R72	Overlap Arg1:T77 Arg2:T110	
T112	Result_or_Value 1599 1618	< 30 ml/min/1,73 m2
R74	Has_Result_or_Value Arg1:T27 Arg2:T112	
R76	Overlap Arg1:T27 Arg2:T77	
R77	Overlap Arg1:T27 Arg2:T110	
R78	Location_of Arg1:T53 Arg2:T33	
R79	Location_of Arg1:T35 Arg2:T54	
T113	Result_or_Value 1768 1780	> 5,2 mmol/l
R80	Has_Result_or_Value Arg1:T54 Arg2:T113	
R81	Overlap Arg1:T54 Arg2:T89	
R82	Overlap Arg1:T54 Arg2:T111	
R83	Has_Quantifier_or_Qualifier Arg1:T89 Arg2:T98	
R84	Overlap Arg1:T89 Arg2:T111	
T114	Quantifier_or_Qualifier 1740 1749	bilateral
#96	AnnotatorNotes T114	C0238767; Bilateral; Spatial Concept
R85	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T114	
T115	Result_or_Value 1909 1918	> 3 x LSN
R89	Has_Result_or_Value Arg1:T37 Arg2:T115	
R90	Has_Result_or_Value Arg1:T56 Arg2:T115	
R91	Has_Quantifier_or_Qualifier Arg1:T92 Arg2:T97	
R92	Location_of Arg1:T57 Arg2:T38	
R93	Location_of Arg1:T58 Arg2:T39	
R94	Experiences Arg1:T78 Arg2:T86	
R95	Experiences Arg1:T78 Arg2:T83	
R96	Experiences Arg1:T78 Arg2:T79	
R97	Before Arg1:T81 Arg2:T79	
R98	Before Arg1:T81 Arg2:T82	
R99	Experiences Arg1:T80 Arg2:T79	
R100	Experiences Arg1:T80 Arg2:T81	
R101	Experiences Arg1:T80 Arg2:T82	
T116	Result_or_Value 2250 2260	> 5 mUI/ml
R102	Has_Result_or_Value Arg1:T42 Arg2:T116	
T117	Result_or_Value 2208 2226	resultado positivo
#97	AnnotatorNotes T117	C1446409; Positive; Finding
R103	Has_Result_or_Value Arg1:T42 Arg2:T117	
R104	Experiences Arg1:T78 Arg2:T42	
R105	Experiences Arg1:T80 Arg2:T42	
R106	Has_Age Arg1:T84 Arg2:T85	
R107	Experiences Arg1:T84 Arg2:T94	
R108	Experiences Arg1:T90 Arg2:T43	
R109	Before Arg1:T43 Arg2:T101	
R110	Experiences Arg1:T90 Arg2:T41	
R111	Overlap Arg1:T101 Arg2:T41	
R113	Before Arg1:T43 Arg2:T65	
R114	Experiences Arg1:T78 Arg2:T81	
R115	Experiences Arg1:T78 Arg2:T82	
R116	Experiences Arg1:T80 Arg2:T86	
R117	Experiences Arg1:T80 Arg2:T83	
R30	Overlap Arg1:T36 Arg2:T92	
R65	Overlap Arg1:T37 Arg2:T92	
R73	Overlap Arg1:T56 Arg2:T92	
#98	AnnotatorNotes T96	C1709323; Open Label Study; Research Activity
#99	AnnotatorNotes T95	C1709323; Open Label Study; Research Activity
#100	AnnotatorNotes T98	C1709323; Open Label Study; Research Activity
#101	AnnotatorNotes T97	C1709323; Open Label Study; Research Activity
A15	Experiencer T61 Patient
A16	Experiencer T63 Patient
A17	Experiencer T66 Patient
A18	Experiencer T68 Other
A19	Experiencer T78 Patient
A20	Experiencer T80 Patient
A21	Experiencer T84 Patient
A22	Experiencer T87 Other
A23	Experiencer T90 Patient
